



Divi's Laboratories Limited

April 22, 2017

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Stock Code: DIVISLAB

Stock Code: 532488

Dear Sir/ Madam,

**Sub: Warning letter issued by US-FDA for the company's Unit-II at
Visakhapatnam, Andhra Pradesh**

Further to our earlier communication dated 8th April, 2017 to the Stock Exchanges, we wish to update that the US-FDA has issued a Warning Letter for the company's Unit-II at Visakhapatnam.

Divi's Laboratories responded to the US-FDA inspection observations with an appropriate remediation process to overcome the deficiencies observed. As part of our commitments, we have also provided periodic updates to the US-FDA.

In the Import Alert issued, US-FDA has exempted several products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh. We will continue to supply these active ingredients to meet its obligations to our customers.


Divi's Labs, along with external consultants and subject matter experts, are working to address the concerns of the US-FDA and is making all efforts to fully meet the compliance requirements. We will respond to this Warning Letter with a detailed plan within the stipulated time.

This is for your information and records.

Thanking you,

Yours faithfully

For **Divi's Laboratories Limited**


L. Kishore Babu
Chief Financial Officer



“An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company”

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460, CIN : L24110TG1990PLC011854

E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com